Exelixis
EXEL
#1647
Rank
ยฃ7.50 B
Marketcap
ยฃ27.22
Share price
0.11%
Change (1 day)
50.71%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

EPS for Exelixis (EXEL)

EPS in 2023 (TTM): ยฃ0.22

According to Exelixis's latest financial reports the company's current EPS (TTM) is ยฃ0.21. In 2022 the company made an earnings per share (EPS) of ยฃ0.43 a decrease over its 2021 EPS that were of ยฃ0.56.

EPS history for Exelixis from 2000 to 2023

Annual EPS

Year EPS Change
2023 (TTM)ยฃ0.22-47.89%
2022ยฃ0.43-22.97%
2021ยฃ0.56100%
2020ยฃ0.28-65.09%
2019ยฃ0.80-53.91%
2018ยฃ1.73333.96%
2017ยฃ0.40-260.61%
2016-ยฃ0.25-58.75%
2015-ยฃ0.60-42.45%
2014-ยฃ1.055.3%
2013-ยฃ0.9943.48%
2012-ยฃ0.69-264.29%
2011ยฃ0.42-165.88%
2010-ยฃ0.64-32.54%
2009-ยฃ0.95-17.65%
2008-ยฃ1.1575.86%
2007-ยฃ0.65-25.64%
2006-ยฃ0.888.33%
2005-ยฃ0.81-42.86%
2004-ยฃ1.4230.34%
2003-ยฃ1.09-5.23%
2002-ยฃ1.15-0.65%
2001-ยฃ1.16-51.88%
2000-ยฃ2.41

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
ยฃ2.63 1,135.69%๐Ÿ‡ฌ๐Ÿ‡ง UK
ยฃ2.39 1,022.57%๐Ÿ‡ซ๐Ÿ‡ท France
ยฃ1.37 543.02%๐Ÿ‡บ๐Ÿ‡ธ USA
ยฃ2.99 1,301.34%๐Ÿ‡บ๐Ÿ‡ธ USA
ยฃ10.64 4,894.71%๐Ÿ‡บ๐Ÿ‡ธ USA
ยฃ10.59 4,871.87%๐Ÿ‡บ๐Ÿ‡ธ USA
ยฃ1.40 556.55%๐Ÿ‡บ๐Ÿ‡ธ USA
-ยฃ7.52-3,629.83%๐Ÿ‡บ๐Ÿ‡ธ USA
-ยฃ0.63-396.51%๐Ÿ‡บ๐Ÿ‡ธ USA